Royalty Pharma (RPRX) to Release Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) is anticipated to announce its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Royalty Pharma to post earnings of $1.22 per share and revenue of $742.0030 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:00 AM ET.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.33 by $0.13. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. The business had revenue of $621.99 million during the quarter, compared to analyst estimates of $839.97 million. On average, analysts expect Royalty Pharma to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Royalty Pharma Stock Up 1.2%

Shares of RPRX stock traded up $0.58 during midday trading on Wednesday, reaching $50.12. 294,610 shares of the stock were exchanged, compared to its average volume of 3,476,867. Royalty Pharma has a 1 year low of $31.97 and a 1 year high of $50.25. The firm has a market cap of $28.91 billion, a PE ratio of 37.12, a price-to-earnings-growth ratio of 3.17 and a beta of 0.39. The company’s 50 day moving average is $47.13 and its two-hundred day moving average is $42.26. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88.

Royalty Pharma Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a $0.235 dividend. This represents a $0.94 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Friday, May 15th. Royalty Pharma’s dividend payout ratio is presently 69.63%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RPRX. Wall Street Zen cut shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Citigroup boosted their price objective on shares of Royalty Pharma from $48.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. UBS Group raised their target price on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Finally, Morgan Stanley lifted their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, April 10th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $50.33.

Insider Transactions at Royalty Pharma

In related news, CFO Terrance P. Coyne sold 34,791 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $48.33, for a total value of $1,681,449.03. Following the sale, the chief financial officer directly owned 32,916 shares in the company, valued at approximately $1,590,830.28. The trade was a 51.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $41.09, for a total value of $821,800.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 367,914 shares of company stock worth $16,074,774. Insiders own 18.84% of the company’s stock.

Institutional Investors Weigh In On Royalty Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the company. CIBC Private Wealth Group LLC grew its position in shares of Royalty Pharma by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 446 shares in the last quarter. Larson Financial Group LLC increased its position in Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 306 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of Royalty Pharma by 59.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,405 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 524 shares in the last quarter. Transamerica Financial Advisors LLC lifted its position in shares of Royalty Pharma by 10.7% in the 4th quarter. Transamerica Financial Advisors LLC now owns 5,158 shares of the biopharmaceutical company’s stock worth $199,000 after purchasing an additional 498 shares during the period. Finally, Hilltop Holdings Inc. bought a new position in shares of Royalty Pharma during the third quarter valued at approximately $205,000. 54.35% of the stock is owned by institutional investors.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.